The study by Thomas et al. showed that HER3 expression was essential for pertuzumab efficacy in HER2low pancreatic cancer, and that HER3 expression may be a predictive biomarker for pertuzumab efficacy [31]. The gene discussed is ERBB3; the disease is pancreatic neoplasm.